+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07023835

Evaluating the Effects of Usnoflast on Amyotrophic Lateral Sclerosis in Adults A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study with Open-Label Extension

Led by Zydus Therapeutics Inc. · Updated on 2026-09-01

240

Participants Needed

49

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Usnoflast in adults with Amyotrophic Lateral Sclerosis ALS to study its effects on disease progression, safety, and how the drug works in the body. This phase 2b trial is randomized, double-blind, placebo-controlled, and parallel-group across multiple centers, aiming to assess Usnoflasts efficacy and safety over 36 weeks, followed by an open-label extension. The study addresses the urgent need for new treatments for ALS, a progressive neuromuscular disease. Participants receive either 50 mg or 75 mg doses of Usnoflast or matching placebo capsules twice daily under fasting conditions for 36 weeks. After this period, eligible participants from all groups can join a 16-week open-label extension where everyone receives 75 mg Usnoflast twice daily. This extension helps confirm the long-term safety and effectiveness of Usnoflast. During the study, participants will be regularly assessed for motor function using the ALS Functional Rating Scale-Revised, survival rates, lung function, and biomarkers in blood and cerebrospinal fluid. Researchers will monitor drug levels in plasma and cerebrospinal fluid at specific times after dosing. Safety will be carefully tracked, including any adverse events. The total participation can last up to 52 weeks, including the treatment and extension phases.

CONDITIONS

Brief Title

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Research Team

F

Farheen Shaikh

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here